Join Now

Yearly Archives: 2024

Here’s how Utah earned its No. 1 ranking for innovation

By Natalie Themm | Published December 19, 2024

A new report from the U.’s Kem C. Gardner Policy Institute uncovers the wide-ranging mechanisms driving Utah’s high performance when it comes to innovation output

Posted in BioUtah News | Comments Off on Here’s how Utah earned its No. 1 ranking for innovation

Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

By Natalie Themm | Published December 19, 2024

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics. The program, launching this month, will run for a minimum of three years.

Posted in BioUtah News | Tagged | Comments Off on Teva Announces New Patient Access Program with Direct Relief to Provide Access to Inhalers for Uninsured Patients

Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

By Natalie Themm | Published December 19, 2024

Study Demonstrates RiskScore as a More Accurate Predictor of Breast Cancer Risk, Doubling Accuracy Compared to the Tyrer-Cuzick Model

Posted in BioUtah News | Tagged | Comments Off on Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics

Human Forms and Body Parts Trigger Strong Reactions in the Brain

By Natalie Themm | Published December 19, 2024

Human Forms and Body Parts Trigger Strong Reactions in the Brain

Posted in BioUtah News | Tagged | Comments Off on Human Forms and Body Parts Trigger Strong Reactions in the Brain

Canary Speech and Prism Care Announce Partnership to Enhance Extended Care Through Vocal Biomarker Technology

By Natalie Themm | Published December 19, 2024

Partnership aims to set new industry standards for managing mental health and cognitive conditions

Posted in BioUtah News | Tagged | Comments Off on Canary Speech and Prism Care Announce Partnership to Enhance Extended Care Through Vocal Biomarker Technology

SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

By Natalie Themm | Published December 19, 2024

SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

Posted in BioUtah News | Tagged | Comments Off on SINTX TECHNOLOGIES SECURES PATENT ALLOWANCE FOR WIDE-RANGING SILICON NITRIDE BIOMATERIAL APPLICATIONS

BD Resolves Previously Disclosed SEC Investigation

By Natalie Themm | Published December 19, 2024

BD has reached an agreement with the U.S. SEC to resolve the previously disclosed investigation related to prior public disclosures.

Posted in BioUtah News | Tagged | Comments Off on BD Resolves Previously Disclosed SEC Investigation

NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD

By admin | Published December 12, 2024

VALENCIA, Calif. – Dec. 3, 2024 – Nusano, a physics company transforming the production of radioisotopes, today announced the creation of a Medical Radioisotopes Advisory Board. This panel of internationally recognized leaders in nuclear medicine will provide strategic guidance to Nusano, ensuring its product development aligns with emerging trends and with the needs of cancer […]

Posted in BioUtah News | Comments Off on NUSANO NAMES MEDICAL RADIOISOTOPES ADVISORY BOARD

Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

By admin | Published December 12, 2024

SALT LAKE CITY, Dec. 10, 2024 /PRNewswire/ — Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. Ltd.’s oligonucleotide synthesis facility will take place December 11, 2024, in Ranoli, India. In support of the “Make […]

Posted in BioUtah News | Comments Off on Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility

Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

By admin | Published December 12, 2024

LEHI, Utah, Dec. 10, 2024 /PRNewswire/ — Halia Therapeutics, a biopharmaceutical company at the forefront of developing treatments for chronic inflammation and related disorders, announced today promising topline data resulting in the advancement to the second stage of its Phase 2 clinical trial evaluating HT-6184, a first-in-class allosteric NEK7/NLRP3 inflammasome inhibitor given orally, in patients with lower-risk […]

Posted in BioUtah News | Comments Off on Halia Therapeutics Announces Positive Topline Data and Advances to Second Stage of Phase 2 Clinical Trial for HT-6184 in Patients with Low-Risk Myelodysplastic Syndromes (LR-MDS)

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

By Natalie Themm | Published December 12, 2024

Recursion reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.

Posted in BioUtah News | Tagged | Comments Off on Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

CancerVax Targets Hard to Treat Pancreatic Cancer

By Natalie Themm | Published December 12, 2024

With limited options available to treat Pancreatic Ductal Adenocarcinoma (PDAC), the Company’s Universal Cancer Treatment Platform may provide hope for patients and doctors

Posted in BioUtah News | Tagged | Comments Off on CancerVax Targets Hard to Treat Pancreatic Cancer

A Special Thanks To Our Legacy and Platinum Elite Members